Options for the Treatment of Mucinous Ovarian Carcinoma

Craig, O; Salazar, C; Gorringe, KL

Author(s): Craig, O; Salazar, C; Gorringe, KL;
Details: Publication Year 2021-12,Volume 22,Issue #12,Page 114
Journal Title: Current Treatment Options in Oncology
Publication Type: Review
Abstract: Complete surgical resection is the gold-standard treatment for all mucinous ovarian carcinoma (MOC) cases. Advanced-stage disease is often additionally treated with adjuvant platinum-based chemotherapy; however, these were developed largely against the more common high-grade serous ovarian carcinoma and have low efficacy in treating MOC. More effective therapeutics are needed to treat late-stage and platinum-resistant tumors; however, traditional drug development and clinical trial paradigms are a major challenge for such a rare disease. New approaches to support evidence-based treatment decisions are required, such as registry trials. Recently, a number of targeted therapies have emerged as viable treatment options in other cancer types, and for some of these, the actionable tumor mutations are also seen in MOC. Thus, a promising alternative approach to provide benefit to current MOC patients involves DNA sequencing to identify a tumor's unique mutational profile and allow matching to available targeted agents. Such a pipeline can involve special approval to administer a drug already approved for clinical use in other cancer types to a given MOC patient, or their inclusion in existing ongoing clinical trials, such as basket trials encompassing patients with tumors from a range of anatomical sites. Implementation of such personalized medicine can be boosted using improved pre-clinical models, where through a clinical research collaboration a patient's own tumor cells can be used to a test a range of putative therapies prior to administration in the clinic, enabling selection of the available pharmaceutical/s that give any given patient the best possible chance of cancer remission.
Keywords: Adenocarcinoma, Mucinous/pathology/*therapy; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Appendectomy; *Cytoreduction Surgical Procedures; Female; Humans; *Lymph Node Excision; Molecular Targeted Therapy; Neoplasm Staging; Ovarian Neoplasms/pathology/*therapy; Peritoneum/surgery; *Radiotherapy; *Salpingo-oophorectomy
Department(s): Laboratory Research
PubMed ID: 34773517
Publisher's Version: https://doi.org/10.1007/s11864-021-00904-6
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-09-05 04:42:38

Last Modified: 2025-09-05 04:44:09